Pharmacogenetics and the practice of medicine.
paper
Cited
Public
Unavailable
- Authors
- Roses, A D
- Year
- 2000
- Journal
- Nature
- PMID
- 10866212
- DOI
- 10.1038/35015728
"If it were not for the great variability among individuals medicine might as well be a science and not an art." The thoughts of Sir William Osler in 1892 reflect the view of medicine over the past 100 years. The role of physicians in making the necessary judgements about the medicines that they prescribe is often referred to as an art, reflecting the lack of objective data available to make decisions that are tailored to individual patients. Just over a hundred years later we are on the verge of being able to identify inherited differences between individuals which can predict each patient's response to a medicine. This ability will have far-reaching benefits in the discovery, development and delivery of medicines. Sir William Osler, if he were alive today, would be re-considering his view of medicine as an art not a science.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic strategies to detect genes involved in alcoholism and alcohol-related traits. | 2002 | 12875045 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Estimating the incidence of actionable drug-gene interactions in Japanese patients with major depressive disorder. | Hatano M et al. | β | 2025 | β |
| Sarcoidosis in the Genomic Era: From Genetic Drivers to Tailored Therapies. | Rivera NV et al. | β | 2025 | β |
| Towards precision pain management in veterinary practice: opportunities and barriers. | Jonovski JC et al. | β | 2025 | β |
| Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test. | Delabays B et al. | β | 2024 | β |
| Deciphering single-cell gene expression variability and its role in drug response. | Liu S et al. | β | 2024 | β |
| Does One Size Fits All? | Roldan V et al. | β | 2024 | β |
| Translational research and implementation science: Accelerating the imperative. | Idemyor V | β | 2024 | β |
| Functional genomics in stem cell models: considerations and applications. | Shevade K et al. | β | 2023 | β |
| Pharmacogenetic Guidelines for Psychotropic Drugs: Optimizing Prescriptions in Clinical Practice. | Baldacci A et al. | β | 2023 | β |
| Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions. | McDonnell JM et al. | β | 2023 | β |
| Ξ²1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome. | Fayed MS et al. | β | 2023 | β |
| Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. | Merino D et al. | β | 2022 | β |
| Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. | Magavern EF et al. | β | 2022 | β |
| Modified Taq DNA Polymerase for Allele-Specific Ultra-Sensitive Detection of Genetic Variants. | Lim Y et al. | β | 2022 | β |
| Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements. | Jain N et al. | β | 2022 | β |
| A Decade of Pharmacogenetic Studies in Jordan: AΒ Systemic Review. | Yehya A et al. | β | 2021 | β |
| Pharmacogenetics and Forensic Toxicology: A New Step towards a Multidisciplinary Approach. | Di Nunno N et al. | β | 2021 | β |
| Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder. | Badamasi IM et al. | β | 2021 | β |
| Utilization and uptake of clinical genetics services in high-income countries: A scoping review. | Dragojlovic N et al. | β | 2021 | β |
| X-change symposium: status and future of modern radiation oncology-from technology to biology. | Corradini S et al. | β | 2021 | β |
| GENETIC DUTIES. | Roberts JL et al. | β | 2020 | β |
| The association of two common polymorphisms in miRNAs with diabetes mellitus: A meta-analysis. | Li G et al. | β | 2019 | β |
| Topological Transformation-Based Nanobarcoding for Detection and Enumeration of MicroRNAs and Single Nucleotide Polymorphism. | Yuk JS et al. | β | 2019 | β |
| Use of Pharmacogenetic Drugs by the Dutch Population. | Alshabeeb MA et al. | β | 2019 | β |
| Coinfections and comorbidities in African health systems: At the interface of infectious and noninfectious diseases. | Osakunor DNM et al. | β | 2018 | β |
| From art to science: a new epistemological status for medicine? On expectations regarding personalized medicine. | Wiesing U | β | 2018 | β |
| Genetic Variation in the Dopamine System Influences Intervention Outcome in Children with Cerebral Palsy. | Diaz Heijtz R et al. | β | 2018 | β |
| Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. | Oates JT et al. | β | 2018 | β |
| "He Beat You in the Blood": Knowledge and Beliefs About the Transmission of Traits Among Latinos from Mexico and Central America. | Sandberg JC et al. | β | 2017 | β |
| IL-10 Gene Polymorphisms and Self-Medication With Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs. | Walsh SJ | β | 2017 | β |
| Pharmacogenetics in type 2 diabetes: still a conundrum in clinical practice. | Brunetti A et al. | β | 2017 | β |
| Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. | MacKenzie M et al. | β | 2017 | β |
| Precision medicine in circadian rhythm sleep-wake disorders: current state and future perspectives. | Keijzer H et al. | β | 2017 | β |
| Single-Subject Studies in Translational Nutrition Research. | Schork NJ et al. | β | 2017 | β |
| SNPs in microRNA target sites and their potential role in human disease. | MoszyΕska A et al. | β | 2017 | β |
| A review of consent practices and perspectives for pharmacogenetic testing. | Haga SB et al. | β | 2016 | β |
| Conceptual and terminological confusion around personalised medicine: a coping strategy. | De Grandis G et al. | β | 2016 | β |
| Genome-wide gene-environment interactions on quantitative traits using family data. | Sitlani CM et al. | β | 2016 | β |
| Pharmacogenetics of antiepileptic drugs: A brief review. | Parker D et al. | β | 2016 | β |
| Protein function in precision medicine: deep understanding with machine learning. | Rost B et al. | β | 2016 | β |
| Rolling circle amplification as isothermal gene amplification in molecular diagnostics. | Goo NI et al. | β | 2016 | β |
| Sleep Pharmacogenetics: Personalized Sleep-Wake Therapy. | Holst SC et al. | β | 2016 | β |
| A novel biosensor for quantitative monitoring of on-target activity of paclitaxel. | Townley HE et al. | β | 2015 | β |
| Fluorescence-based detection of single-nucleotide changes in RNA using graphene oxide and DNAzyme. | Hong C et al. | β | 2015 | β |
| Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. | He Y et al. | β | 2015 | β |
| Genetics and health communication: a primer. | Greenberg MS | β | 2015 | β |
| Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study. | HenrΓquez-HernΓ‘ndez LA et al. | β | 2015 | β |
| "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing. | Trinidad SB et al. | β | 2015 | β |
| Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. | Maitland ML et al. | β | 2015 | β |
| Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw. | Fung PL et al. | β | 2015 | β |
| Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas. | Dorfman EH et al. | β | 2015 | β |
| Precision medicine in oncology needs to integrate pharmacogenetic profiling. | Cussenot O et al. | β | 2015 | β |
| Pharmacogenomics of episodic migraine: time has come for a step forward. | Viana M et al. | β | 2014 | β |
| Positive perception of pharmacogenetic testing for psychotropic medications. | Lanktree MB et al. | β | 2014 | β |
| Reliability and Validity Assessment of Mizaj Questionnaire: A Novel Self-report Scale in Iranian Traditional Medicine. | Mojahedi M et al. | β | 2014 | β |
| Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. | Haga SB et al. | β | 2014 | β |
| The possible effects of moral bioenhancement on political privileges and fair equality of opportunity. | Ram-Tiktin E | β | 2014 | β |
| Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences? | Bakker JM et al. | β | 2014 | β |
| Variants of a Thermus aquaticus DNA polymerase with increased selectivity for applications in allele- and methylation-specific amplification. | Drum M et al. | β | 2014 | β |
| Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. | Flannick J et al. | β | 2013 | β |
| Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio. | Lai JY | β | 2013 | β |
| Cardiac channelopathy causing sudden death as revealed by molecular autopsy. | Kauferstein S et al. | β | 2013 | β |
| Delivering pharmacogenetic testing in a primary care setting. | Mills R et al. | β | 2013 | β |
| Gene expression: biomarker of antidepressant therapy? | Menke A | β | 2013 | β |
| Impact of biomarkers on clinical trial risk. | Reid GG et al. | β | 2013 | β |
| Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. | Doble B et al. | β | 2013 | β |
| Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. | Weng L et al. | β | 2013 | β |
| Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse. | Greek R et al. | β | 2013 | β |
| Relationship between gene polymorphisms of two cytokine genes (TNF-Ξ± and IL-6) and occurring of lung cancers in the ethnic group Han of China. | Liang J et al. | β | 2013 | β |
| Systematic reviews of animal models: methodology versus epistemology. | Greek R et al. | β | 2013 | β |
| The impact of genomics on oncology nursing. | Beamer LC et al. | β | 2013 | β |
| Animal models and conserved processes. | Greek R et al. | β | 2012 | β |
| Animal models in an age of personalized medicine. | Greek R et al. | β | 2012 | β |
| Clinically significant psychotropic drug-drug interactions in the primary care setting. | English BA et al. | β | 2012 | β |
| Correlation of polymorphisms of the vascular endothelial growth factor gene and the risk of lung cancer in an ethnic Han group of North China. | Li Y et al. | β | 2012 | β |
| Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. | Cacabelos R et al. | β | 2012 | β |
| Institutional Profile: The Center for Biomarker Research and Personalized Medicine at Virginia Commonwealth University: advancing psychiatric drug treatment. | McClay JL | β | 2012 | β |
| Personalizing medicine: futures present and past. | Tutton R | β | 2012 | β |
| Pharmacogenomics and individualized medicine: translating science into practice. | Crews KR et al. | β | 2012 | β |
| Population biobanking in selected European countries and proposed model for a Polish national DNA bank. | Sak J et al. | β | 2012 | β |
| Professional perspectives about pharmacogenetic testing and managing ancillary findings. | Haga SB et al. | β | 2012 | β |
| Public perspectives about pharmacogenetic testing and managing ancillary findings. | Haga SB et al. | β | 2012 | β |
| Sampling populations of humans across the world: ELSI issues. | Knoppers BM et al. | β | 2012 | β |
| Susceptibility genes and pharmacogenetics in ocular inflammatory disorders. | Liu B et al. | β | 2012 | β |
| The Nuremberg Code subverts human health and safety by requiring animal modeling. | Greek R et al. | β | 2012 | β |
| Treatment Heterogeneity and Individual Qualitative Interaction. | Poulson RS et al. | β | 2012 | β |
| A genetic perspective on nutritional profiles: do we still need them? | Gregori D et al. | β | 2011 | β |
| Detection of single-base mutation in RNA using T4 RNA ligase-based nick-joining or DNAzyme-based nick-generation. | Park K et al. | β | 2011 | β |
| Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. | McClay JL et al. | β | 2011 | β |
| Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. | McClay JL et al. | β | 2011 | β |
| Informed consent in the context of pharmacogenomic research: ethical considerations. | Howard HC et al. | β | 2011 | β |
| Isothermal discrimination of single-nucleotide polymorphisms via real-time kinetic desorption and label-free detection of DNA using silicon photonic microring resonator arrays. | Qavi AJ et al. | β | 2011 | β |
| Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. | Vizirianakis IS | β | 2011 | β |
| Part 1: background, methodology, and clinical adoption of pharmacogenetics. | Deenen MJ et al. | β | 2011 | β |
| Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. | Haga SB et al. | β | 2011 | β |
| The institutional review board is an impediment to human research: the result is more animal-based research. | Rice MJ | β | 2011 | β |
| Consumers' views of pharmacogenetics--A qualitative study. | Haddy CA et al. | β | 2010 | β |
| Gene therapy and enhancement for diabetes (and other diseases): the multiplicity of considerations. | Bertolaso M et al. | β | 2010 | β |
| Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. | LΓ³pez-Cuenca A et al. | β | 2010 | β |
| Genetics of osteoporosis. | Ralston SH et al. | β | 2010 | β |
| Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. | Higgs J et al. | β | 2010 | β |
| Plant chemical genetics. | McCourt P et al. | β | 2010 | β |
| Usefulness of direct sequencing of pooled DNA for SNP identification and allele-frequency determination compatible with a common disease/common variant hypothesis. | Kim MK et al. | β | 2010 | β |
| XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer. | Zhu LB et al. | β | 2010 | β |
| Beyond personalized medicine. | MΓΈldrup C | β | 2009 | β |
| [Biomarkers: "Found in translation"]. | Lockhart BP et al. | β | 2009 | β |
| Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. | Holmes MV et al. | β | 2009 | β |
| Genetic approach to elucidation of sasang constitutional medicine. | Kim BY et al. | β | 2009 | β |
| Genotyping of single nucleotide polymorphisms using base-quenched probe: a method does not invariably depend on the deoxyguanosine nucleotide. | Luo G et al. | β | 2009 | β |
| HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. | Nolan D | β | 2009 | β |
| Nurses' genetic/genomics competencies when medication therapy is guided by pharmacogenetic testing: children with mental health disorders as an exemplar. | Prows CA et al. | β | 2009 | β |
| Personalized medicine and disruptive innovation: implications for technology assessment. | Schulman KA et al. | β | 2009 | β |
| Pharmacogenetics in acute lymphoblastic leukemia. | Cheok MH et al. | β | 2009 | β |
| Pharmacogenetics in cardiovascular antithrombotic therapy. | MarΓn F et al. | β | 2009 | β |
| Pharmacogenetics of anxiolytic drugs. | Tiwari AK et al. | β | 2009 | β |
| Progress in genetic studies of pain and analgesia. | Lacroix-Fralish ML et al. | β | 2009 | β |
| Atherothrombosis and plaque heterology: different location or a unique disease? | Slevin M et al. | β | 2008 | β |
| Current developments in genomics and personalized health care: impact on public health. | Manamperi A | β | 2008 | β |
| Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. | Shields AE et al. | β | 2008 | β |
| Exploring emerging technologies using metaphors--a study of orphan drugs and pharmacogenomics. | Boon W et al. | β | 2008 | β |
| How can we realize the promise of personalized antidepressant medicines? | Holsboer F | β | 2008 | β |
| Interlocking transcriptomics, proteomics and toponomics technologies for brain tissue analysis in murine hippocampus. | Bode M et al. | β | 2008 | β |
| Legal update: living with the Genetic Information Nondiscrimination Act. | Erwin C | β | 2008 | β |
| Pharmacogenetics in drug discovery and development: a translational perspective. | Roses AD | β | 2008 | β |
| Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. | Lekman M et al. | β | 2008 | β |
| Pharmacogenetic testing: legal considerations for consent, privacy and disclosure. | Romeo-Malanda S et al. | β | 2008 | β |
| Pharmacogenetic testing: not as simple as it seems. | Haga SB et al. | β | 2008 | β |
| Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. | Shields AE et al. | β | 2008 | β |
| Role of pharmacogenomics in drug discovery and development. | Surendiran A et al. | β | 2008 | β |
| Same anesthetic technique for urethroplasty in identical twins. | Spyridonidou A et al. | β | 2008 | β |
| Susceptibility genes & modifiers for cardiac arrhythmias. | Schulze-Bahr E | β | 2008 | β |
| The great ambivalence: factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. | Barr M et al. | β | 2008 | β |
| Chemical genetic interrogation of natural variation uncovers a molecule that is glycoactivated. | Zhao Y et al. | β | 2007 | β |
| Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism. | Chantarangsu S et al. | β | 2007 | β |
| Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). | Roses AD et al. | β | 2007 | β |
| Developing a European grid infrastructure for cancer research: vision, architecture and services. | Tsiknakis M et al. | β | 2007 | β |
| Genetics and diagnostic refinement. | van den Oord E et al. | β | 2007 | β |
| Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. | Greenfield S et al. | β | 2007 | β |
| Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. | Corkindale D et al. | β | 2007 | β |
| Multi-target therapeutics: when the whole is greater than the sum of the parts. | Zimmermann GR et al. | β | 2007 | β |
| Personalized medicine: using effective partnering for managing the risk of legal liability. | Roth M | β | 2007 | β |
| Pharmacogenetics and asthma: false hope or new dawn? | Hall IP et al. | β | 2007 | β |
| Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. | Grossman I et al. | β | 2007 | β |
| Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. | Grant SF et al. | β | 2007 | β |
| SNPs in disease gene mapping, medicinal drug development and evolution. | Shastry BS | β | 2007 | β |
| Various pharmacogenetic aspects of antiepileptic drug therapy: a review. | Mann MW et al. | β | 2007 | β |
| A public health genetic approach for schizophrenia. | Danese A | β | 2006 | β |
| Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. | Ross JR et al. | β | 2006 | β |
| Context, ethics and pharmacogenetics. | Hedgecoe AM | β | 2006 | β |
| [Economic evaluation in the pharmacogenetics and pharmacogenomics era: a light in the darkness?]. | Soto Alvarez J | β | 2006 | β |
| Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. | Nolan D et al. | β | 2006 | β |
| Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. | Seo D et al. | β | 2006 | β |
| Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. | Depondt C et al. | β | 2006 | β |
| Lay perspective on pharmacogenomics: a literature review. | Nielsen LF et al. | β | 2006 | β |
| Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. | Millan MJ | β | 2006 | β |
| New cyanine-oligonucleotide conjugates: relationships between chemical structures and properties. | Lartia R et al. | β | 2006 | β |
| Pharmacogenetics approach to therapeutics. | Koo SH et al. | β | 2006 | β |
| Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment. | Blackhall FH et al. | β | 2006 | β |
| Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. | Joly Y et al. | β | 2006 | β |
| Pharmacogenomics of acute leukemia. | Cheok MH et al. | β | 2006 | β |
| Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. | Phillips KA et al. | β | 2006 | β |
| Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. | Lerman C et al. | β | 2006 | β |
| Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies. | Vidal-Taboada JM et al. | β | 2006 | β |
| Tag/anti-tag liquid-phase primer extension array: a flexible and versatile genotyping platform. | Li JG et al. | β | 2006 | β |
| The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. | Woelderink A et al. | β | 2006 | β |
| The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation. | Kroczak TJ et al. | β | 2006 | β |
| The influence of genetics on nicotine dependence and the role of pharmacogenetics in treating the smoking habit. | Chatkin JM | β | 2006 | β |
| The potential of pharmacogenetics in the treatment of epilepsy. | Depondt C | β | 2006 | β |
| WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. | Yi M et al. | β | 2006 | β |
| A science of the individual: implications for a medical school curriculum. | Childs B et al. | β | 2005 | β |
| Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. | Shields AE et al. | β | 2005 | β |
| Clinical pharmacogenetics of irinotecan (CPT-11). | Ando Y et al. | β | 2005 | β |
| Definition and clinical importance of haplotypes. | Crawford DC et al. | β | 2005 | β |
| Design and synthesis of a 3'-O-allyl photocleavable fluorescent nucleotide as a reversible terminator for DNA sequencing by synthesis. | Ruparel H et al. | β | 2005 | β |
| DNA repair inhibition: a selective tumour targeting strategy. | Madhusudan S et al. | β | 2005 | β |
| Experimental designs for reliable detection of linkage disequilibrium in unstructured random population association studies. | Ball RD | β | 2005 | β |
| Functional Genomics meets neurodegenerative disorders. Part II: application and data integration. | Hoerndli F et al. | β | 2005 | β |
| Genetic aspects of immune-mediated adverse drug effects. | Bugelski PJ | β | 2005 | β |
| Genetic variations related to hypertension: a review. | Tanira MO et al. | β | 2005 | β |
| Human genetic research: emerging trends in ethics. | Knoppers BM et al. | β | 2005 | β |
| Measuring the value of pharmacogenomics. | Phillips KA et al. | β | 2005 | β |
| New technologies and screening strategies for hepatotoxicity: use of in vitro models. | Dambach DM et al. | β | 2005 | β |
| Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking. | Caron L et al. | β | 2005 | β |
| Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report. | Corrigan OP | β | 2005 | β |
| Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. | Ando M et al. | β | 2005 | β |
| Pharmacogenomics in hypertension: present practicalities and future potential. | Brain N et al. | β | 2005 | β |
| Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. | Hakonarson H et al. | β | 2005 | β |
| Sequencing drug response with HapMap. | Lin M et al. | β | 2005 | β |
| Stored tissue samples: through the confidentiality maze. | Joly Y et al. | β | 2005 | β |
| The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. | Madhusudan S et al. | β | 2005 | β |
| The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. | Zheng HX et al. | β | 2005 | β |
| The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. | Serretti A et al. | β | 2005 | β |
| The pharmacological treatment of neonatal pain. | Tibboel D et al. | β | 2005 | β |
| The psychotherapy of genetics. | McDaniel SH | β | 2005 | β |
| Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. | Jiang WY | β | 2005 | β |
| Trick or treat: the effect of placebo on the power of pharmacogenetic association studies. | Singer C et al. | β | 2005 | β |
| Workshop Introduction: Personalized medicine: desirable, affordable, attainable? | Gurwitz D et al. | β | 2005 | β |
| Analysis of sequence variations in several human genes using phosphoramidite bond DNA fragmentation and chip-based MALDI-TOF. | Smylie KJ et al. | β | 2004 | β |
| Challenges of implementing pharmacogenetics in the critical care environment. | Freeman BD et al. | β | 2004 | β |
| Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. | Hughes DA et al. | β | 2004 | β |
| Developing products for personalized medicine: NIH Research Tools Policy applications. | Gupta R et al. | β | 2004 | β |
| Digital detection of genetic mutations using SPC-sequencing. | Ruparel H et al. | β | 2004 | β |
| Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. | Ezzeldin H et al. | β | 2004 | β |
| Electrical detection of viral DNA using ultramicroelectrode arrays. | Nebling E et al. | β | 2004 | β |
| Ensuring the appropriate use of genetic tests. | Burke W et al. | β | 2004 | β |
| Ethical implications of pharmacogenetics--do slippery slope arguments matter? | Schubert L | β | 2004 | β |
| Gene expression profiling: from microarrays to medicine. | Weeraratna AT et al. | β | 2004 | β |
| Genetics of hypertension: lessons learnt from mendelian and polygenic syndromes. | Dominiczak AF et al. | β | 2004 | β |
| Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. | Fishbain DA et al. | β | 2004 | β |
| Genetic testing: the community pharmacist's perspective. | Sansgiry SS et al. | β | 2004 | β |
| Genetic variation and pharmacogenomics: concepts, facts, and challenges. | Hoehe MR et al. | β | 2004 | β |
| Genetic variation, classification and 'race'. | Jorde LB et al. | β | 2004 | β |
| Human controlled ovarian hyperstimulation outcome is a polygenic trait. | de Castro F et al. | β | 2004 | β |
| Induction of G1 cell cycle arrest and P15INK4b expression by ECRG1 through interaction with Miz-1. | Zhao N et al. | β | 2004 | β |
| Integrating pharmacogenetics into society: in search of a model. | Webster A et al. | β | 2004 | β |
| In vitro modulation of inflammatory cytokine production by three lipid emulsions with different fatty acid compositions. | Reimund JM et al. | β | 2004 | β |
| Pharmacogenetics in immunosuppressive therapy: the best thing since TDM? | van Gelder T et al. | β | 2004 | β |
| Pharmacogenetic testing, informed consent and the problem of secondary information. | Netzer C et al. | β | 2004 | β |
| Principles of pharmacogenetics--implications for the anaesthetist. | Iohom G et al. | β | 2004 | β |
| Prospective medicine: the role for genomics in personalized health planning. | Langheier JM et al. | β | 2004 | β |
| Real-time genotyping with oligonucleotide probes containing locked nucleic acids. | Ugozzoli LA et al. | β | 2004 | β |
| Revisiting the Clinical Validity of Multiplex Genetic Testing in Complex Diseases: Reply to Janssens et al. | Yang Q et al. | β | 2004 | β |
| Straightforward detection of SNPs in double-stranded DNA by using exonuclease III/nuclease S1/PNA system. | Ren B et al. | β | 2004 | β |
| Tailored medicine: whom will it fit? The ethics of patient and disease stratification. | Smart A et al. | β | 2004 | β |
| Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. | van Delden J et al. | β | 2004 | β |
| The complex interplay among factors that influence allelic association. | Zondervan KT et al. | β | 2004 | β |
| The future of genetic testing for drug response. | Morris-Rosendahl DJ et al. | β | 2004 | β |
| The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. | Zheng HX et al. | β | 2004 | β |
| Theoretical aspects of genomic variation screening using DNA microarrays. | Vainrub A et al. | β | 2004 | β |
| The pharmacogenomics of selective serotonin reuptake inhibitors. | Serretti A et al. | β | 2004 | β |
| The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis. | Del Vecchio A et al. | β | 2004 | β |
| The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. | Walker DK | β | 2004 | β |
| A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. | Viswanathan PC et al. | β | 2003 | β |
| A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. | Haas DW et al. | β | 2003 | β |
| Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. | BlΓΌher M et al. | β | 2003 | β |
| Antihypertensive therapy: special focus on drug interactions. | Maas R et al. | β | 2003 | β |
| Candidate gene case-control studies. | Daly AK | β | 2003 | β |
| Cardiovascular pharmacogenomics: current status, future prospects. | Anderson JL et al. | β | 2003 | β |
| cDNA microarray and proteomic approaches in the study of brain diseases: focus on schizophrenia and Alzheimer's disease. | Marcotte ER et al. | β | 2003 | β |
| Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. | Phillips MS et al. | β | 2003 | β |
| Digital genotyping using molecular affinity and mass spectrometry. | Kim S et al. | β | 2003 | β |
| Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. | Shah J | β | 2003 | β |
| Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. | Lerman C et al. | β | 2003 | β |
| Genetic polymorphisms, drugs, and proarrhythmia. | Roden DM | β | 2003 | β |
| Genomic profiling to promote a healthy lifestyle: not ready for prime time. | Haga SB et al. | β | 2003 | β |
| Genomics and pediatric research. | Boright AP et al. | β | 2003 | β |
| Health promotion in a changing world: preparing for the genomics revolution. | Wilkinson JM et al. | β | 2003 | β |
| Host-environment medicine: a primary care model for the age of genomics. | Rabinowitz PM et al. | β | 2003 | β |
| Individualized pharmacogenetic therapy: a critical analysis. | Schmedders M et al. | β | 2003 | β |
| Intramolecular dimers: a new design strategy for fluorescence-quenched probes. | Johansson MK et al. | β | 2003 | β |
| Issues in newborn screening. | Saxena A | β | 2003 | β |
| Is treatment-resistant depression a unique subtype of depression? | Fagiolini A et al. | β | 2003 | β |
| Leukotriene antagonists. | Davern TJ et al. | β | 2003 | β |
| Neuropeptide gene polymorphisms and human behavioural disorders. | Inui A | β | 2003 | β |
| Novel aspects of renal organic anion transporters. | Eraly SA et al. | β | 2003 | β |
| PET and the role of in vivo molecular imaging in personalized medicine. | Pither R | β | 2003 | β |
| Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. | Lesko LJ et al. | β | 2003 | β |
| Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. | Norbert PW et al. | β | 2003 | β |
| Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. | Danesi R et al. | β | 2003 | β |
| Pharmacogenetics of the major polymorphic metabolizing enzymes. | Daly AK | β | 2003 | β |
| [Pharmacogenetic studies: evaluation guidelines for research ethics committees. Scientific background and legal framework (I)]. | RodrΓguez-Villanueva J et al. | β | 2003 | β |
| Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges. | Issa AM | β | 2003 | β |
| Pharmacogenomics of drugs affecting the cardiovascular system. | Siest G et al. | β | 2003 | β |
| Pharmacologically regulated induction of silent mutations (PRISM): combined pharmacological and genetic approaches for learning and memory. | Frankland PW et al. | β | 2003 | β |
| POCUS: mining genomic sequence annotation to predict disease genes. | Turner FS et al. | β | 2003 | β |
| Policy before practice: genetic discrimination reviewed. | Epps PG | β | 2003 | β |
| Population stratification and spurious allelic association. | Cardon LR et al. | β | 2003 | β |
| Rediscovering the sweet spot in drug discovery. | Brown D et al. | β | 2003 | β |
| Signatures of natural selection in the human genome. | Bamshad M et al. | β | 2003 | β |
| Single nucleotide polymorphism genotyping using locked nucleic acid (LNA). | Mouritzen P et al. | β | 2003 | β |
| The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. | Murphy GM et al. | β | 2003 | β |
| The drugs don't work: expectations and the shaping of pharmacogenetics. | Hedgecoe A et al. | β | 2003 | β |
| The epidemiological night where all patients are black: will pharmacogenetics shed some light? | de Gaetano G et al. | β | 2003 | β |
| The future of antidepressant pharmacotherapy. | Baldwin D et al. | β | 2003 | β |
| [The genome and its metaphors. Detectives, heroes or prophets?]. | Davo MC et al. | β | 2003 | β |
| The new genetics of schizophrenia. | McDonald C et al. | β | 2003 | β |
| The potential and limitations of personalised medicine in primary care. | Hapgood R | β | 2003 | β |
| The potential and limitations of personalized medicine in the doctor-patient relationship. | Hapgood R | β | 2003 | β |
| The reality of pharmacogenomics: optimizing therapeutic decision making. | Lee CR et al. | β | 2003 | β |
| The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. | Zabetian CP et al. | β | 2003 | β |
| Treatment of ovarian cancer: new strategies. | DiSaia PJ et al. | β | 2003 | β |
| Understanding attitudes toward clinical research. | Schulman KA | β | 2003 | β |
| Using genome-wide mapping in the mouse to identify genes that influence drug response. | Watters JW et al. | β | 2003 | β |
| Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. | Yang P et al. | β | 2002 | β |
| A novel procedure for simple and efficient genotyping of single nucleotide polymorphisms by using the Zn2+-cyclen complex. | Kinoshita-Kikuta E et al. | β | 2002 | β |
| Autism: in search of susceptibility genes. | Lamb JA et al. | β | 2002 | β |
| Candidate gene approach for pharmacogenetic studies. | Ring HZ et al. | β | 2002 | β |
| Developing novel treatments for mood disorders: accelerating discovery. | Tamminga CA et al. | β | 2002 | β |
| Emerging ethical issues in pharmacogenomics: from research to clinical practice. | Freund CL et al. | β | 2002 | β |
| Functional organization of the yeast proteome by systematic analysis of protein complexes. | Gavin AC et al. | β | 2002 | β |
| Genetic approaches to the molecular understanding of type 2 diabetes. | McCarthy MI et al. | β | 2002 | β |
| Genetic dissection of quantitative trait loci specifying sedative/hypnotic sensitivity to ethanol: mapping with interval-specific congenic recombinant lines. | Bennett B et al. | β | 2002 | β |
| Genetic strategies to detect genes involved in alcoholism and alcohol-related traits. | Dick DM et al. | β | 2002 | β |
| Genetic testing. | Burke W | β | 2002 | β |
| Genome-based pharmacogenetics and the pharmaceutical industry. | Roses AD | β | 2002 | β |
| Genomics and the prediction of xenobiotic toxicity. | Meyer UA et al. | β | 2002 | β |
| High-density genotyping and linkage disequilibrium in the human genome using chromosome 22 as a model. | Remm M et al. | β | 2002 | β |
| Implications of circadian gene expression in kidney, liver and the effects of fasting on pharmacogenomic studies. | Kita Y et al. | β | 2002 | β |
| Irinotecan in small-cell lung cancer. | Ando Y et al. | β | 2002 | β |
| Is pharmacological prevention of Alzheimer's a realistic goal? | Zandi PP et al. | β | 2002 | β |
| Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity. | Hosking LK et al. | β | 2002 | β |
| MALDI-TOF mass spectrometry-based SNP genotyping. | Pusch W et al. | β | 2002 | β |
| Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance. | Brazell C et al. | β | 2002 | β |
| Medical genetics: 1. Clinical teratology in the age of genomics. | Polifka JE et al. | β | 2002 | β |
| Methods of in vitro toxicology. | Eisenbrand G et al. | β | 2002 | β |
| Microarrays and genetic epidemiology: a multipurpose tool for a multifaceted field. | Dalma-Weiszhausz DD et al. | β | 2002 | β |
| Microarrays as cancer keys: an array of possibilities. | Mohr S et al. | β | 2002 | β |
| Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. | Johnson JA et al. | β | 2002 | β |
| Molecular profiles of inflammatory myopathies. | Greenberg SA et al. | β | 2002 | β |
| Multiplexed microsphere-based flow cytometric assays. | Kellar KL et al. | β | 2002 | β |
| Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. | Watters JW et al. | β | 2002 | β |
| Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. | Vizirianakis IS | β | 2002 | β |
| Pharmacogenetic investigation of smoking cessation treatment. | Lerman C et al. | β | 2002 | β |
| Pharmacogenetic screening and therapeutic drugs. | Steimer W et al. | β | 2002 | β |
| Pharmacogenetics in affective disorders. | Serretti A et al. | β | 2002 | β |
| Pharmacogenetics of asthma. | Fenech A et al. | β | 2002 | β |
| Pharmacogenetics of treatment with leukotriene modifiers. | Wechsler ME et al. | β | 2002 | β |
| Pharmacogenomics for the treatment of dementia. | Cacabelos R | β | 2002 | β |
| Pharmacogenomics/pharmacoproteomics Europe. | Meister W | β | 2002 | β |
| Plasmodium, human and Anopheles genomics and malaria. | Hoffman SL et al. | β | 2002 | β |
| Population screening of single-nucleotide polymorphisms exemplified by analysis of 8000 alleles. | EkstrΓΈm PO et al. | β | 2002 | β |
| Pyrosequencing technology and the need for versatile solutions in molecular clinical research. | Berg LM et al. | β | 2002 | β |
| Role of case reports in medical literature: bathwater has not been shown to cleanse babies. | Helfaer MA | β | 2002 | β |
| Single nucleotide polymorphism detection by combinatorial fluorescence energy transfer tags and biotinylated dideoxynucleotides. | Tong AK et al. | β | 2002 | β |
| Single nucleotide polymorphism seeking long term association with complex disease. | Kirk BW et al. | β | 2002 | β |
| SNPs--where's the beef? | Roses AD | β | 2002 | β |
| Solid phase capturable dideoxynucleotides for multiplex genotyping using mass spectrometry. | Kim S et al. | β | 2002 | β |
| Spotting the future. | Nicholson TL et al. | β | 2002 | β |
| The application of genetics to the discovery of better medicines. | Pettipher R et al. | β | 2002 | β |
| The discovery of susceptibility genes for mental disorders. | Cloninger CR | β | 2002 | β |
| The effects of analgesia in the vulnerable infant during the perinatal period. | van Lingen RA et al. | β | 2002 | β |
| The genetic basis of variability in drug responses. | Roden DM et al. | β | 2002 | β |
| The hunt for new genes and polymorphisms that can control the response to drugs. | Sheffield LJ | β | 2002 | β |
| The interface of preclinical evaluation with clinical testing of antiepileptic drugs: role of pharmacogenomics and pharmacogenetics. | Holmes GL | β | 2002 | β |
| The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. | Zheng H et al. | β | 2002 | β |
| Tuning PCR specificity by chemically modified primer probes. | Strerath M et al. | β | 2002 | β |
| ACTIVITY: a database on DNA/RNA sites activity adapted to apply sequence-activity relationships from one system to another. | Ponomarenko JV et al. | β | 2001 | β |
| After the genome: DNA and human disease. | Davies K | β | 2001 | β |
| Antidepressant drug discovery in the postgenomic era. | Holsboer F | β | 2001 | β |
| A semi-automated system for analysis and storage of SNPs. | Lehnert V et al. | β | 2001 | β |
| Association study designs for complex diseases. | Cardon LR et al. | β | 2001 | β |
| Cambridge Healthtech Institute's Third Annual Conference on human genetic variation. 16-18 October 2000, Philadelphia, Pennsylvania, USA. | Diehl SR et al. | β | 2001 | β |
| Candidate gene case-control association studies: advantages and potential pitfalls. | Daly AK et al. | β | 2001 | β |
| Categorizing genetic tests to identify their ethical, legal, and social implications. | Burke W et al. | β | 2001 | β |
| Clinical practice in the new era. A fusion of molecular biology and classical medicine is transforming the way we look at and treat diseases. | Papavassiliou AG | β | 2001 | β |
| Closing the gaps in genetics legislation and policy: a report by the new york state task force on life and the law. | Carroll AM et al. | β | 2001 | β |
| Consent and privacy in pharmacogenetic testing. | Robertson JA | β | 2001 | β |
| Costs and prevention of adverse drug reactions. | Janaje Munasinghe TM et al. | β | 2001 | β |
| Current concepts on the genetics of asthma. | Hakonarson H et al. | β | 2001 | β |
| Detecting rare mutations associated with cancer risk. | Wilson VL | β | 2001 | β |
| Development of novel biomedicine based on genome science. | Baba Y | β | 2001 | β |
| DNA microarray gene expression analysis technology and its application to neurological disorders. | Greenberg SA | β | 2001 | β |
| DNA microarrays in medical practice. | Aitman TJ | β | 2001 | β |
| DNA microarrays in neuropsychopharmacology. | Marcotte ER et al. | β | 2001 | β |
| DNA sequencing using biotinylated dideoxynucleotides and mass spectrometry. | Edwards JR et al. | β | 2001 | β |
| Drug target pharmacogenomics: an overview. | Johnson JA | β | 2001 | β |
| Early rheumatoid arthritis: a medical emergency? | Moreland LW et al. | β | 2001 | β |
| Empowering primary care health professionals in medical genetics: how soon? How fast? How far? | Greendale K et al. | β | 2001 | β |
| Ethical and legal implications of pharmacogenomics. | Rothstein MA et al. | β | 2001 | β |
| Ethical and policy issues in genetic testing. | Ross LF | β | 2001 | β |
| Ethical, social and legal implications of pharmacogenomics: a critical review. | Moldrup C | β | 2001 | β |
| Exploiting human genetic variation in drug discovery and development. | Jazwinska EC | β | 2001 | β |
| Family consent and the pursuit of better medicines through genetic research. | Renegar G et al. | β | 2001 | β |
| Functional genomics and cardiovascular drug discovery. | Lee RT | β | 2001 | β |
| [Gene chip (DNA array): the future is now!]. | Busquets X et al. | β | 2001 | β |
| General introduction to the importance of genomics in food biotechnology and nutrition. | Verrips CT et al. | β | 2001 | β |
| Genetics and genomics in neuropsychopharmacology: the impact on drug discovery and development. | Hurko O | β | 2001 | β |
| Genetic susceptibility to adverse drug reactions. | Pirmohamed M et al. | β | 2001 | β |
| Genomics and behavior. Toward behavioral genomics. | McGuffin P et al. | β | 2001 | β |
| Genomics and medicine. Dissecting human disease in the postgenomic era. | Peltonen L et al. | β | 2001 | β |
| Genomics, proteomics, and nurses. | Monsen RB | β | 2001 | β |
| Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo(1). | Phillips RM et al. | β | 2001 | β |
| Graphical Abstract. | Wess G et al. | β | 2001 | β |
| Homogeneous assays for single-nucleotide polymorphism typing using AlphaScreen. | Beaudet L et al. | β | 2001 | β |
| How will pharmacogenetics impact the future of research and development? | Roses AD | β | 2001 | β |
| Impact of human genome sequencing for in silico target discovery. | Sanseau P | β | 2001 | β |
| Integrated regional genetic services: current and future provision. | Donnai D et al. | β | 2001 | β |
| Medicinal Chemistry: Challenges and Opportunities. | Wess G et al. | β | 2001 | β |
| Molecular approaches to studying nutrient metabolism and function: an array of possibilities. | Hirschi KD et al. | β | 2001 | β |
| Molecular diagnostics in monogenic and multifactorial forms of type 2 diabetes. | McCarthy MI et al. | β | 2001 | β |
| Mood disorders in children and adolescents: an NIMH perspective. | Hyman SE | β | 2001 | β |
| New approaches to antiarrhythmic therapy, Part I: emerging therapeutic applications of the cell biology of cardiac arrhythmias. | Members of the Sicilian Gambit | β | 2001 | β |
| Nuts and bolts of psychiatric genetics: building on the Human Genome Project. | Evans KL et al. | β | 2001 | β |
| Pharmacogenetic determinants of anti-cancer drug activity and toxicity. | Danesi R et al. | β | 2001 | β |
| Pharmacogenetics. | McCarthy A | β | 2001 | β |
| Pharmacogenetics and pharmacogenomics. | Pirmohamed M | β | 2001 | β |
| Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. | Ingelman-Sundberg M | β | 2001 | β |
| Pharmacogenetics for the individualization of psychiatric treatment. | Arranz MJ et al. | β | 2001 | β |
| [Pharmacogenetics of cytochromes P450: practical implications]. | Jaillon P | β | 2001 | β |
| Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. | Ulrich CM et al. | β | 2001 | β |
| Pharmacogenetics: the ethical context. | Thomas SM | β | 2001 | β |
| Pharmacogenetics: the Rx perspective. | Renegar G et al. | β | 2001 | β |
| Pharmacogenomics: implications for laboratory medicine. | Schmitz G et al. | β | 2001 | β |
| Pharmacogenomics of cystic fibrosis. | Pollard HB et al. | β | 2001 | β |
| Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. | Scorer CA | β | 2001 | β |
| Psoriasis: the future. | Kirby B et al. | β | 2001 | β |
| Rapid characterization of DNA oligomers and genotyping of single nucleotide polymorphism using nucleotide-specific mass tags. | Abdi F et al. | β | 2001 | β |
| READIT: a novel technology used in the interrogation of nucleic acid sequences for single-nucleotide polymorphisms. | Tsongalis GJ et al. | β | 2001 | β |
| Recent progress in livestock genomics and potential impact on breeding programs. | Georges M | β | 2001 | β |
| RNA-mediated interference as a tool for identifying drug targets. | O'Neil NJ et al. | β | 2001 | β |
| Science, medicine, and the future: Postgenomic technologies: hunting the genes for common disorders. | Mathew C | β | 2001 | β |
| The end of the beginning for genomic medicine. | Bailey D et al. | β | 2001 | β |
| The genetics of type 2 diabetes. | Gloyn AL et al. | β | 2001 | β |
| The human medicine project has started: place your bets now. | Roses AD | β | 2001 | β |
| The pharmacogenomics of HIV therapy. | Pirmohamed M et al. | β | 2001 | β |
| The promise of human genetic databases. | Lowrance WW | β | 2001 | β |
| Toxicogenetics in drug development. | Park BK et al. | β | 2001 | β |
| A method for fine mapping quantitative trait loci in outbred animal stocks. | Mott R et al. | β | 2000 | β |
| Biomedical discovery with DNA arrays. | Young RA | β | 2000 | β |
| Can complex genetic diseases be solved? (and a PS on PXE). | Luft FC | β | 2000 | β |
| Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy. | Danesi R et al. | β | 2000 | β |
| Idiosyncratic reactions to drugs: can medicine response profiles provide a dynamic drug surveillance system? | Roses AD | β | 2000 | β |
| Pharmacogenomics and schizophrenia. | Kawanishi Y et al. | β | 2000 | β |
| The challenge of validating genetic testing. | Kristoffersson U | β | 2000 | β |